Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
Conclusion: The unique combined mechanism of action and favorable efficacy and safety profile of dapagliflozin–metformin XR support consideration of this fixed-dose combination as a treatment option for patients with T2DM. Keywords: fixed-dose combination therapy, metformin, SGLT2 inhibitor
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Clinical Trials | Dapagliflozin | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fortamet | Forxiga | Health | Health Management | Heart | Metabolic Syndrome | Metformin | Obesity | SGLT2 Inhibitors | Study | University of Wisconsin | Weight Loss